Provention bio to host a may 19, 2022 virtual investor event focused on the potential commercial launch of teplizumab later this year

Red bank, n.j. , may 12, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb) (the "company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will host an investor event on thursday, may 19, 2022 focused on the potential commercial launch of teplizumab in the second half of this year.
PRVB Ratings Summary
PRVB Quant Ranking